LAUSANNE, Switzerland and GENEVA, June 23 /PRNewswire-FirstCall/ -- Debiotech and STMicroelectronics (NYSE: STM) today introduced first evaluation prototypes of a unique miniaturized insulin-delivery pump. The tiny device can be mounted on a disposable skin patch to provide continuous insulin infusion, enabling substantial advancements in the availability, treatment efficiency and the quality of life of diabetes patients. The breakthrough Nanopump, which relies on microfluidic MEMS (Micro-Electro-Mechanical System) technology, has successfully passed initial testing stages and is now ready to enter volume manufacturing.
The highly miniaturized disposable insulin pump combines Debiotech's expertise in insulin delivery systems with ST's strengths in manufacturing high-volume silicon-based microfluidic devices. The Nanopump is less than one fourth the size of existing insulin-pump devices and can be worn as a nearly invisible patch on the skin.
Microfluidic technology also provides better control of the administered insulin doses, more closely mimicking the natural secretion of insulin from the pancreas, while detecting potential malfunctions of the pump to further protect patients.
As a disposable device, manufactured using high-volume semiconductor processing technologies, the MEMS-based Nanopump is also much more affordable, allowing the patient or the health system to avoid the substantial up-front investment typically associated with current pump solutions.
Insulin pump therapy, or Continuous Subcutaneous Insulin Infusion
(CSII), is an increasingly attractive alternative to individual insulin
injections that must be administered several times a day. With CSII, the
patient is connected to a programmable pump in
'/>"/>
| SOURCE STMicroelectronics Copyright©2008 PR Newswire. All rights reserved |